Papantoni Evangelia, Ntatsis Konstantinos, Kyziridis Dimitrios, Kalakonas Apostolos, Hristakis Christos, Tentes Antonios Apostolos
Metaxa Cancer Hospital, Piraeus, Greece.
J BUON. 2021 Jul-Aug;26(4):1647-1652.
Pseudomyxoma peritonei is treated with cytoreductive surgery (CRS) combined and hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC). The purpose of this study was to report the20-year experience of one surgical team inCRS and HIPEC for PMP of appendiceal origin.
Retrospective study of the files of patients with PMP of appendiceal origin that underwent CRS+HIPEC. Morbidity and hospital mortality were recorded. Clinical and histopathologic variables were correlated to survival and recurrence.
The files of 41 patients with PMP of appendiceal origin that underwent CRS+HIPEC from 1999-2018 were retrieved. The mortality and the morbidity rates were 2.4% and 29.3%, respectively. The 5- and 8-year survival rate was 68.3%. The completeness of cytoreduction, and the extent of previous surgery were identified as the prognostic indicators of survival. The recurrence rate was 32.5% with the completeness of cytoreduction, the histologic type of the tumor being the prognostic indicator.
CRS in combination with perioperative intraperitoneal chemotherapy is a safe and effective treatment in the management of PMP of appendiceal origin.
腹膜假黏液瘤采用细胞减灭术（CRS）联合术中腹腔内热灌注化疗（HIPEC）进行治疗。本研究的目的是报告一个手术团队针对阑尾源性腹膜假黏液瘤进行CRS和HIPEC的20年经验。
对接受CRS+HIPEC治疗的阑尾源性腹膜假黏液瘤患者的病历进行回顾性研究。记录发病率和医院死亡率。将临床和组织病理学变量与生存率和复发情况相关联。
检索了1999年至2018年间41例接受CRS+HIPEC治疗的阑尾源性腹膜假黏液瘤患者的病历。死亡率和发病率分别为2.4%和29.3%。5年和8年生存率为68.3%。细胞减灭的完整性和既往手术范围被确定为生存的预后指标。复发率为32.5%，细胞减灭的完整性、肿瘤的组织学类型为预后指标。
CRS联合围手术期腹腔内化疗是治疗阑尾源性腹膜假黏液瘤的一种安全有效的方法。
